Christine A Strick

20030096323, May 22, 2003

Jul 24, 2002

10/202107

Larry James - Preston CT, US
Lorraine Lebel - North Stonington CT, US
Frank Menniti - Mystic CT, US
Christine Strick - Lisbon CT, US

Pfizer Inc.

C12Q001/00
G01N033/567

435/007210, 435/004000

The invention features a method of screening for an agent that inhibits intracellular phosphodiesterase 10A activity, comprising administering an agent to striatal medium spiny neurons and submaximally activating adenylate cyclase, administering an agent to striatal medium spiny neurons and submaximally activating guanylate cyclase, measuring cAMP generation and cGMP generation in the cells, and calculating the cAMP ECand the cGMP EC, wherein the agent is identified as a PDE10A inhibitor if the ratio of cAMP EC/cGMP ECis comparable to the ratio produced by administration of papaverine under the same assay conditions. Also featured are rat PDE10A polynucleotide and polypeptide sequences.

20030121069, Jun 26, 2003

Dec 19, 2002

10/324617

Frank Menniti - Mystic CT, US
Christopher Schmidt - Old Lyme CT, US
Jeffrey Stock - North Stonington CT, US
Christine Strick - Lisbon CT, US

Pfizer Inc.

C12Q001/68
A01K067/027
C12N005/06

800/018000, 435/006000, 435/354000

The invention features non-human mammals and animal cells that contain a targeted disruption of a phosphodiesterase 10A (PDE10A) gene.

20050026236, Feb 3, 2005

Jul 8, 2004

10/887276

Larry James - Preston CT, US
Lorraine Lebel - North Stonington CT, US
Frank Menniti - Mystic CT, US
Christine Strick - Lisbon CT, US

C12Q001/42
A61K031/7076

435021000, 514045000, 514048000, 514049000

The invention features a method of screening for an agent that inhibits intracellular phosphodiesterase 10A activity, comprising administering an agent to striatal medium spiny neurons and submaximally activating adenylate cyclase, administering an agent to striatal medium spiny neurons and submaximally activating guanylate cyclase, measuring cAMP generation and cGMP generation in the cells, and calculating the cAMP ECand the cGMP EC, wherein the agent is identified as a PDE10A inhibitor if the ratio of cAMP EC/cGMP ECis comparable to the ratio produced by administration of papaverine under the same assay conditions. Also featured are rat PDE10A polynucleotide and polypeptide sequences.

57862125, Jul 28, 1998

May 6, 1996

8/596382

Larry C. James - Norwich CT
Christine A. Strick - Lisbon CT

Pfizer Inc. - New York NY

C12N 1581
C12N 1511
C12P 2102
C07H 2104

4353201

This invention relates to modified Yarrowia lipolytica LEU2 gene promoters; modified Y. lipolytica LEU2 genes comprising such modified Y. lipolytica LEU2 gene promoters; and vectors comprising such modified Y. lipolytica LEU2 genes. This invention also relates to vectors comprising a Y. lipolytica DNA sequence LEU2 genes. This invention also relates to vectors comprising a Y. lipolytica DNA sequence sufficient for integrative transformation of Y. lipolytica; vectors which comprise a nucleotide sequence coding for a polypeptide and a promoter functional in Y. lipolytica operably linked thereto; E. coli transformants which comprise vectors according to this invention; Y. lipolytica transormants which comprise an expression vector according to this invention; methods of producing Y. lipolytica transformants comprising multiple integrated expression vectors; strains of Y. lipolytica useful in the preparation of such transformants; methods of producing polypeptides with certain of the Y.